Sellas claims Phase 3 win on AML cancer vaccine
Sellas Life Sciences' cancer vaccine succeeded in a Phase 3 trial of certain acute myeloid leukemia patients, the company said Tuesday. Sellas is developing galinpepimut-S, which it calls GPS for short ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.